Deena
Mousa is a freshman at Yale University majoring in Molecular, Cellular,
and Developmental Biology with a particular interest in public health.
Her work as a biomedical researcher and data analyst has complemented
rigorous academic coursework and allowed her to develop an in-depth
understanding of the research process as a whole. Ms. Mousa is the
founder of Sanguis Therapeutics, a pharmaceutical startup designed to promote her patented medical device, Hemostat V-Seal.
Deena Mousa, the prodigal high-school student, invented a mixture of chemical components that can stop severe bleeding faster than the medicines currently used in hospitals. At
17, Dina Mousa, the Egyptian student, invented a medical composition
that could stop severe bleeding at a faster ratio than the medicines. In a lab at the Albany College of Pharmacy – that agreed on hosting her, provided
that she worked as an assistant for a year in their lab. It was only
after a year’s lapse that she would be able to use their equipment to
develop her own research project. Ms. Mousa is planning to study molecular biology in university next year after fast-tracking through high school.
Having created Hemostat V-Seal as her school’s final project, the
researcher secured the pre-patent last year, and filed two provisional
applications for the final patent in the USA. As she now processes the
FDA (the US Food and Drug Administration) approval, Mousa aspires to
introduce it to the market in the coming months. Now, she has done the R&D part of the medicine. She wants to learn about the business and financial side so she can bring it to the market, influence, and save lives. Dina is also hoping that if she can succeed in one market, she can bring it to Egypt next.
No comments:
Post a Comment